FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
about
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies.Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map?Preoperative predictors for early recurrence of resectable pancreatic cancer.Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study.Recent Advances in Pancreatic Cancer Surgery.Evolving treatment landscape for early and advanced pancreatic cancer.Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions.What treatment in 2017 for inoperable pancreatic cancers?Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer.Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.The Role of Venous and Arterial Resection in Pancreatic Cancer Surgery.Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.Multi-disciplinary management of locally advanced pancreatic cancer with irreversible electroporation.Surgical strategies and novel therapies for locally advanced pancreatic cancer.Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.Cutting Through Confusion: Multimodality Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both?Contemporary Management of Localized Resectable Pancreatic Cancer.The clinical benefit of hyperthermia in pancreatic cancer: a systematic review.Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma.Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer.Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers.Medical oncology and pancreatic cancer: what the radiologist needs to know.[Early stage pancreatic cancer].Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer.Recent advances in the management of pancreatic adenocarcinoma.Improving outcomes in patients with resectable pancreatic cancer.Pancreatic cancer: Current status and Challenges.Pharmacoepigenetics and pharmacoepigenomics of gastrointestinal cancers.Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer.Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study.
P2860
Q33441785-CE089950-3AF7-462C-8CEB-AE15D51CF6AFQ33775311-F7862BF8-925C-4315-899C-E44501170C6EQ34537580-F9E5D14F-BD20-4031-90A7-24930B29409DQ37265792-CA5740E2-3D34-41E0-8693-4BBCC8D0D6A8Q37576457-D4E8D831-B87A-4BB2-B304-675B2E6BFC2BQ38406521-DECCF5BC-349E-401C-A21B-DB5207A7C904Q38602630-135B7A2D-83AB-4F49-88E3-2442BDCB2497Q38624806-7D2DB1AA-B8CB-4419-8EF7-4BC6C2EC33C8Q38637958-F5C81D4D-1EC6-41C5-B693-E702044C428AQ38689025-F9379D3A-A1E0-404B-9AD0-27F486C7973AQ38722475-D2BC6FA4-8C04-4075-8B2F-F04C40A4B8F3Q38753432-521110A0-85B6-4043-AAB4-B9DACE0F7AD9Q39018587-7A093924-2E6B-48B2-9D34-FF7C5BEA8711Q39023169-442877CD-2CB7-4389-8431-5595AA28CC7CQ39034733-FDC45EF1-9259-481A-9BF6-900C02ABD698Q39286021-D23C6AA9-937D-46AB-B81D-28FED31C1D0AQ39312912-46BAE9B9-1792-4940-9C42-1488C1364312Q39313846-26520FBE-F380-4286-865A-5393EE852698Q40179597-51C67187-DBBC-4F50-A78F-BF1C1F28E360Q41573034-B67D5390-A8A5-4C22-9C56-8CA441A8EBDCQ41651225-7CFEE1EC-A177-462A-B58F-0CC1D4338B92Q42374126-4979FDA9-D94F-4E07-8424-B2BA21F8B290Q47161355-70185577-CD06-4762-853C-1813B7C0C13BQ47716584-93BFC4DB-3DA3-42AC-BCE3-DDEBF0B81BA8Q47822083-6E7D6090-97DE-46DC-BE11-D0A56713E8DAQ47926291-B7770658-0E07-4F24-94C3-82CD16F75360Q47998977-D884C1B1-67C3-4B03-BA69-48FF8E76D813Q48194931-2EDC5A56-A8E4-4E79-8727-4E1EB1C4DA1BQ48221094-EC8962B4-E0F8-410A-9978-30ADB517F163Q48293161-6B54DB45-9187-44C2-AD03-7E89B4DAE87CQ49504793-512C4B8D-A33F-4199-B9EC-40294321B25EQ49630827-A74AFC46-C13D-48D3-8C82-7E16A4BC11BFQ49883875-CFD69D96-D5F1-434B-B488-C402B00EC702Q50012127-8DD2A06E-30DB-4EC7-A92B-729897CF79BEQ50072347-95F2C6C0-C5D8-4CC3-8A65-E43DAAB7483AQ50142675-941FD9BD-E4DE-4683-B5C9-4621663AD731Q50195669-F19BC085-E93C-440D-BC42-1246E41CD9E0Q50252299-47D16942-8101-4852-8A26-8DEABBB1CF25Q51176310-67E93C55-1AFE-4AAC-9841-D7197FA99DE3Q52802886-8611E781-D19D-4CF9-BCE3-9E2E68443408
P2860
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
FOLFIRINOX for locally advance ...... d patient-level meta-analysis.
@en
type
label
FOLFIRINOX for locally advance ...... d patient-level meta-analysis.
@en
prefLabel
FOLFIRINOX for locally advance ...... d patient-level meta-analysis.
@en
P2093
P2860
P31
P1433
P1476
FOLFIRINOX for locally advance ...... d patient-level meta-analysis.
@en
P2093
Andrea Wang-Gillam
Bas Groot Koerkamp
Bassel F El-Rayes
Berend R Beumer
Casper H van Eijck
Eran Sadot
Eric A Mellon
Florian Hohla
Jason E Faris
P2860
P304
P356
10.1016/S1470-2045(16)00172-8
P50
P577
2016-05-06T00:00:00Z